A new trading day began on Tuesday, with Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) stock price up 4.27% from the previous day of trading, before settling in for the closing price of $561.49. REGN’s price has ranged from $525.99 to $1211.20 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 22.10% over the last five years. Meanwhile, its annual earnings per share averaged -12.04%. With a float of $104.85 million, this company’s outstanding shares have now reached $107.80 million.
The firm has a total of 15106 workers. Let’s measure their productivity. In terms of profitability, gross margin is 84.47%, operating margin of 28.32%, and the pretax margin is 33.66%.
Regeneron Pharmaceuticals, Inc (REGN) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Regeneron Pharmaceuticals, Inc is 3.60%, while institutional ownership is 87.19%. The most recent insider transaction that took place on Nov 01 ’24, was worth 844,610. In this transaction EVP Commercial of this company sold 1,000 shares at a rate of $844.61, taking the stock ownership to the 12,931 shares. Before that another transaction happened on Nov 01 ’24, when Company’s Officer proposed sale 1,000 for $844.61, making the entire transaction worth $844,610.
Regeneron Pharmaceuticals, Inc (REGN) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of 10.02 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -12.04% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 4.46% during the next five years compared to 15.74% growth over the previous five years of trading.
Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) Trading Performance Indicators
Here are Regeneron Pharmaceuticals, Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 3.95. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.48. Likewise, its price to free cash flow for the trailing twelve months is 17.38.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 38.29, a number that is poised to hit 8.75 in the next quarter and is forecasted to reach 44.29 in one year’s time.
Technical Analysis of Regeneron Pharmaceuticals, Inc (REGN)
Analysing the last 5-days average volume posted by the [Regeneron Pharmaceuticals, Inc, REGN], we can find that recorded value of 0.86 million was lower than the volume posted last year of 0.98 million. As of the previous 9 days, the stock’s Stochastic %D was 71.07%. Additionally, its Average True Range was 24.69.
During the past 100 days, Regeneron Pharmaceuticals, Inc’s (REGN) raw stochastic average was set at 21.64%, which indicates a significant decrease from 58.33% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 49.70% in the past 14 days, which was higher than the 34.07% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $648.59, while its 200-day Moving Average is $858.50. Now, the first resistance to watch is $593.35. This is followed by the second major resistance level at $601.20. The third major resistance level sits at $615.31. If the price goes on to break the first support level at $571.39, it is likely to go to the next support level at $557.28. Should the price break the second support level, the third support level stands at $549.43.
Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) Key Stats
With a market capitalization of 63.68 billion, the company has a total of 109,325K Shares Outstanding. Currently, annual sales are 14,202 M while annual income is 4,413 M. The company’s previous quarter sales were 3,789 M while its latest quarter income was 917,700 K.
